Halofuginone prevents outer retinal degeneration in a mouse model of light-induced retinopathy

PLoS One. 2024 Mar 27;19(3):e0300045. doi: 10.1371/journal.pone.0300045. eCollection 2024.

Abstract

Photoreceptor cell death can cause progressive and irreversible visual impairments. Still, effective therapies on retinal neuroprotection are not available. Hypoxia-inducible factors (HIFs) are transcriptional factors which strongly regulate angiogenesis, erythropoiesis, intracellular metabolism, and programed cell death under a hypoxic or an abnormal metabolic oxidative stress condition. Therefore, we aimed to unravel that inhibition of HIFs could prevent disease progression in photoreceptor cell death, as recent studies showed that HIFs might be pathologic factors in retinal diseases. Adult male balb/cAJcl (8 weeks old; BALB/c) were used to investigate preventive effects of a novel HIF inhibitor halofuginone (HF) on a murine model of light-induced retinopathy. After intraperitoneal injections of phosphate-buffered saline (PBS) or HF (0.4 mg/kg in PBS) for 5 days, male BALB/c mice were subjected to a dark-adaption to being exposed to a white LED light source at an intensity of 3,000 lux for 1 hour in order to induce light-induced retinal damage. After extensive light exposure, retinal damage was evaluated using electroretinography (ERG), optical coherence tomography (OCT), and TUNEL assay. Light-induced retinal dysfunction was suppressed by HF administration. The amplitudes of scotopic a-wave and b-wave as well as that of photopic b-wave were preserved in the HF-administered retina. Outer retinal thinning after extensive light exposure was suppressed by HF administration. Based on the TUNEL assay, cell death in the outer retina was seen after light exposure. However, its cell death was not detected in the HF-administered retina. Halofuginone was found to exert preventive effects on light-induced outer retinal cell death.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Electroretinography
  • Male
  • Mice
  • Piperidines*
  • Quinazolinones*
  • Retina / pathology
  • Retinal Degeneration* / drug therapy
  • Retinal Degeneration* / etiology
  • Retinal Degeneration* / prevention & control

Substances

  • halofuginone
  • Piperidines
  • Quinazolinones

Grants and funding

Its work was supported by Grants-in-Aid for Scientific Research (KAKENHI, number 15 K10881, and 18 K09424) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to T.K. and (KAKENHI, number 20 K18393) from the MEXT to Y.M. and JST SPRING (number JPMJSP2123) to D.L. The funding organization had no role in the design or conduct of this research.